BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence
about
Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical ImplicationsTranscription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) GeneSpotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectivesThe dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutationsGenetic Testing in Differentiated Thyroid Carcinoma: Indications and Clinical ImplicationsTERT promoter mutations in thyroid cancerMutation Profile of Well-Differentiated Thyroid Cancer in AsiansPersonalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterationsCIViC databaseDiagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy.BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrenceIntegrated genomic characterization of papillary thyroid carcinoma2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerHobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinomaA meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinomaThe Role of Central Neck Lymph Node Dissection in the Management of Papillary Thyroid CancerEvaluation of molecular diagnostic approaches for the detection of BRAF p.V600E mutations in papillary thyroid cancer: Clinical implications.BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases.Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer.An improved model for the hTERT promoter quadruplexThe Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.Outcome of papillary thyroid microcarcinoma: Study of 1,990 cases.GLI1 Transcription Factor Affects Tumor Aggressiveness in Patients With Papillary Thyroid Cancers.Clinical Characteristics and Prognostic Significance of TERT Promoter Mutations in Cancer: A Cohort Study and a Meta-Analysis.Clinical utility of RAS mutations in thyroid cancer: a blurred picture now emerging clearer.BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients.Association of telomerase reverse transcriptase promoter mutations with clinicopathological features and prognosis of thyroid cancer: a meta-analysis.BRAF(V600E) mutation is highly prevalent in thyroid carcinomas in the young population in Fukushima: a different oncogenic profile from ChernobylAssociation of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC.Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas.Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.Optimal Cut-Off Values of Lymph Node Ratio Predicting Recurrence in Papillary Thyroid Cancer.Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.Low Prevalence of Somatic TERT Promoter Mutations in Classic Papillary Thyroid CarcinomaDUSP4/MKP2 overexpression is associated with BRAF(V600E) mutation and aggressive behavior of papillary thyroid cancer.TERT Promoter Mutations and Tumor Persistence/Recurrence in Papillary Thyroid Cancer.BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patientsTelomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma.TERT promoter Mutation and Its Association with Clinicopathological Features and Prognosis of Papillary Thyroid Cancer: A Meta-analysisRelationship of Focally Amplified Long Noncoding on Chromosome 1 (FAL1) lncRNA with E2F Transcription Factors in Thyroid Cancer.
P2860
Q26738705-63D18A08-E293-468F-9089-E054D5500614Q26739925-685FE035-F11A-4DA0-98B4-D87EC5BEAA3EQ26751274-42FD39DE-3577-4F97-B07E-3B82C5A6466BQ26753387-D4E53E71-FAE4-4F2C-8DC3-2B63D623419FQ26765085-4BAAAF5B-8C3B-48FA-822E-7076F2923C41Q26770808-21748393-C466-4091-A855-67C1400B907CQ26782322-03AA6604-C567-42D1-8B6D-F698A64CA2A3Q27027491-0599A51E-147A-4DE0-AC53-7D91AD0B5900Q27612411-915963B0-BE50-40DF-BBC6-13C44885F632Q27853057-E6185D1E-2FA4-4AD0-B28B-4E594FE54DA3Q28075975-A9DC9D6A-64EB-47C4-84E9-D39F85981E12Q28251986-757903F1-8F0C-4AAC-8D2A-9AB46C5BE891Q30367068-7974E46B-983B-4497-9FF7-5EEF4B536FBAQ33591794-CE207B27-A389-4617-8274-2C0DFFF04821Q33656624-C6B956CA-8F21-4900-9C0C-924C475E7216Q33810411-736EBAA8-3E0A-4846-980B-6A0459F79B6AQ33821945-97686285-2C35-4E9F-AAEF-D278C30284FBQ33875906-FD84D2B7-BE83-420F-B770-16F6E4674304Q35441872-3B6A2523-5D30-495B-84D9-DDF2088D4B69Q35530780-A7141720-32A7-471C-9E8F-552100702D73Q35692478-ECB74071-A35A-43DD-98F6-42C46C32650CQ35753601-78A97CE5-94F8-4AB9-ABFF-FF171798602FQ35857790-BA39747E-4313-4A71-9507-A8DA36C2825EQ35901458-023CE658-FEB1-4981-A4AF-5FBEA00BFAD5Q35906046-236C6454-9236-4DD0-A302-D8B7ECD1FE35Q35985808-A4467932-D150-4FEF-AF97-442AE47B71EBQ36221232-5C8B4BF7-89F5-455D-AF25-272EF47E6231Q36301491-0EB99C90-381B-4305-9608-EDE5FDD45E8EQ36339926-9B33A2D8-7E2D-4F37-B352-FC5E9D8ACF1AQ36452225-0176B7E2-BEDE-462E-8559-E8BBDA629EAAQ36560914-1975302F-1E0B-40D7-82E0-CD3464EB4D20Q36566991-4DD4EC43-25B7-4502-8CEE-A7B26642FD30Q36618887-028AB5C3-EDCF-4CA5-A426-A17D7D1520D4Q36716977-6D809337-899A-4439-9C92-C788624CCDB4Q36833914-1CD1FA2F-C778-4AC7-9564-5269AE14965CQ37097535-E665D0BB-638F-4533-A45E-F0B4EB0F5DE7Q37109755-E3B18F63-A06E-4F41-9B5E-06F6A7657306Q37317414-5D240D01-7436-4FB6-A457-5778A1C0B9AAQ37408393-683A17A2-7BEA-42EB-8DA2-A495D4BAB97BQ37624102-E9C82AAC-3A36-406D-8EF5-29EE627A44AA
P2860
BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
BRAF V600E and TERT promoter m ...... cancer with highest recurrence
@ast
BRAF V600E and TERT promoter m ...... cancer with highest recurrence
@en
BRAF V600E and TERT promoter m ...... ancer with highest recurrence.
@nl
type
label
BRAF V600E and TERT promoter m ...... cancer with highest recurrence
@ast
BRAF V600E and TERT promoter m ...... cancer with highest recurrence
@en
BRAF V600E and TERT promoter m ...... ancer with highest recurrence.
@nl
altLabel
BRAF V600E and TERT Promoter M ...... Cancer With Highest Recurrence
@en
prefLabel
BRAF V600E and TERT promoter m ...... cancer with highest recurrence
@ast
BRAF V600E and TERT promoter m ...... cancer with highest recurrence
@en
BRAF V600E and TERT promoter m ...... ancer with highest recurrence.
@nl
P2093
P2860
P3181
P356
P1476
BRAF V600E and TERT promoter m ...... cancer with highest recurrence
@en
P2093
Avaniyapuram Kannan Murugan
Guangwu Zhu
Justin Bishop
Martha A Zeiger
Mingzhao Xing
Rengyun Liu
Xiaoli Liu
P2860
P304
P3181
P356
10.1200/JCO.2014.55.5094
P407
P577
2014-09-01T00:00:00Z